294 related articles for article (PubMed ID: 31180819)
1. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsuda C; Nakamoto Y; Kotake M; Kurachi K; Egawa T; Yasumasa K; Murata K; Ikawa O; Shinji S; Murotani K; Matsui S; Teramukai S; Tomita N; Sugihara K;
J Clin Oncol; 2019 Aug; 37(22):1886-1894. PubMed ID: 31180819
[TBL] [Abstract][Full Text] [Related]
2. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
[TBL] [Abstract][Full Text] [Related]
3. Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.
Ishiguro M; Mochizuki H; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Kanemitsu Y; Ueno H; Ishikawa T; Uetake H; Matsui S; Teramukai S; Sugihara K
BMC Cancer; 2012 Jul; 12():281. PubMed ID: 22769569
[TBL] [Abstract][Full Text] [Related]
4. Is there no need to discuss adjuvant chemotherapy in stage II colon cancer patients with high tumor budding and lymphovascular invasion?
Zenger S; Gurbuz B; Can U; Erginoz E; Ozata IH; Yilmaz SP; Taskin OC; Peker O; Adsay V; Balik E; Bugra D
Langenbecks Arch Surg; 2023 Mar; 408(1):127. PubMed ID: 36973561
[TBL] [Abstract][Full Text] [Related]
5. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
[TBL] [Abstract][Full Text] [Related]
6. Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial).
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsui S; Teramukai S; Murotani K; Ajioka Y; Shimazaki H; Maeda A; Takuma K; Yoshida T; Kambara T; Matsuda K; Takagane A; Tomita N; Sugihara K;
Am J Surg Pathol; 2020 Dec; 44(12):1685-1698. PubMed ID: 32868525
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening program.
Pihlmann Kristensen M; Korsgaard U; Timm S; Hansen TF; Zlobec I; Hager H; Kjær-Frifeldt S
Hum Pathol; 2024 Apr; 146():15-22. PubMed ID: 38428823
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer.
Hu JM; Chou YC; Wu CC; Hsiao CW; Lee CC; Chen CT; Hu SI; Liu WT; Jao SW
J Chin Med Assoc; 2016 Sep; 79(9):477-88. PubMed ID: 27329402
[TBL] [Abstract][Full Text] [Related]
9. Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer.
Lee VWK; Chan KF
Pathol Res Pract; 2018 Mar; 214(3):402-407. PubMed ID: 29487008
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
Yun HR; Kim HC; Yun SH; Lee WY
Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
12. Tumor Budding as a Predictive Marker of Relapse and Survival in Patients With Stage II Colon Cancer.
Saito K; Okuyama T; Miyazaki S; Oi H; Mitsui T; Noro T; Takeshita E; Ono Y; Urahashi T; Tajima H; Yoshitomi H
In Vivo; 2022; 36(4):1820-1828. PubMed ID: 35738585
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive values of tumour budding in stage IV colorectal cancer.
Nagata K; Shinto E; Yamadera M; Shiraishi T; Kajiwara Y; Okamoto K; Mochizuki S; Hase K; Kishi Y; Ueno H
BJS Open; 2020 Aug; 4(4):693-703. PubMed ID: 32472647
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
15. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam.
Dao TV; Nguyen CV; Nguyen QT; Vu HTN; Phung HT; Bui OT; Nguyen DK; Luong BV; Tran TV
Cancer Control; 2020; 27(1):1073274820968883. PubMed ID: 33136444
[TBL] [Abstract][Full Text] [Related]
17. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
19. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M;
Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
Sadahiro S; Tsuchiya T; Sasaki K; Kondo K; Katsumata K; Nishimura G; Kakeji Y; Baba H; Sato S; Koda K; Yamaguchi Y; Morita T; Matsuoka J; Usuki H; Hamada C; Kodaira S
Ann Oncol; 2015 Nov; 26(11):2274-80. PubMed ID: 26347106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
